Celastrol, which targets IL-2/CD25 binding inhibition, induces T cell-mediated antitumor activity in melanoma
European Journal of Pharmacology · 2024
DOI: 10.1016/j.ejphar.2023.176239 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Pharmacology, 2024. Verfasst von Okki Cho und 5 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Pharmacoimmunology, Integrated Research Institute of Pharmaceutical Sciences and BK21 FOUR Team for Advanced Program for SmartPharma Le…. Hauptthemen laut MEDLINE: Melanoma. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 46 Literaturangaben. Gefördert von: Ministry of Education, Science and Technology, Catholic University of Korea, National Research Foundation of Korea.
Abstract (Originalsprache)
Interleukin-2 (IL-2) induces contrasting immune responses depending on its binding receptor subunit; thus, selective receptor binding is considered a key challenge in cancer therapeutic strategies. In this study, we aimed to investigate the inhibition of IL-2 action and antitumor activity of celastrol (CEL), a compound identified in a screen for IL-2/CD25 binding inhibitors, and to elucidate the underlying role of CEL in immune cells. We found that CEL selectively impairs the binding of IL-2 and CD25 and directly binds to IL-2 but not to CD25. CEL significantly suppressed the proliferation and signaling of IL-2-dependent murine T cells and interfered with IL-2-responsive STAT5 phosphorylation in IL-2 reporter cells and human PBMCs. After confirming the impact of CEL on IL-2, we evaluated its antitumor activity in C57BL/6 mice bearing B16F10 tumors and found that CEL significantly inhibited tumor growth by increasing CD8+ T cells. We also found that CEL did not inhibit tumor growth in T cell-deficient BALB/c nude mice, suggesting that its activity was mediated by the T-cell response. Moreover, combination therapy with low-dose CEL and a TNFR2 antagonist synergistically improved the therapeutic efficacy of the individual monotherapies by increasing the ratio of intratumoral CD8/Treg cells and suppressing Foxp3 expression. These findings suggest that CEL, which inhibits CD25 binding by targeting IL-2, exerts antitumor activity by mediating the T-cell response and could be a promising candidate for combination therapy in cancer immunotherapy against melanoma.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Pharmacoimmunology, Integrated Research Institute of Pharmaceutical Sciences and BK21 FOUR Team for Advanced Program for SmartPharma Leaders, College of Pharmacy, The Catholic University of Korea, 43 Jibon…
Förderung
- Ministry of Education, Science and Technology
- Catholic University of Korea
- National Research Foundation of Korea
Zitieren
APA
Cho, O., Lee, J. W., Jeong, Y. J., Kim, L. K., Jung, B. K., & Heo, T. H. (2024). Celastrol, which targets IL-2/CD25 binding inhibition, induces T cell-mediated antitumor activity in melanoma. European Journal of Pharmacology. https://doi.org/10.1016/j.ejphar.2023.176239
Vancouver
Cho O, Lee JW, Jeong YJ, Kim LK, Jung BK, Heo TH. Celastrol, which targets IL-2/CD25 binding inhibition, induces T cell-mediated antitumor activity in melanoma. European Journal of Pharmacology. 2024. doi:10.1016/j.ejphar.2023.176239
BibTeX
@article{Cho2024,
author = {Cho, Okki and Lee, Joong-Woon and Jeong, Young-Jin and Kim, Lee Kyung and Jung, Bo-Kyung and Heo, Tae-Hwe},
title = {Celastrol, which targets IL-2/CD25 binding inhibition, induces T cell-mediated antitumor activity in melanoma},
journal = {European Journal of Pharmacology},
year = {2024},
doi = {10.1016/j.ejphar.2023.176239}
}
EUVIMED